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Risk of Benzene-induced Leukemia
Predicted from the Pliofilm Cohort
Kenny S. Crump
ICF Kaiser International, Ruston, Louisiana
This report updates the risk assessment by Crump and Allen for benzene-induced leukemia that
was based on a cohort exposed to benzene in the manufacture of Pliofilm. The present study
derives new risk estimates using data from follow-up through 1987 (whereas the earlier
assessment only had follow-up available through 1978) and uses new exposure information for
this cohort developed by Paustenbach et al. that accounts for a number of factors that were
unknown or not fully evaluated in earlier exposure assessments. There was a significant excess
of acute myelocytic or acute monocytic leukemia (AMML) (8-10 observed, 1.61 expected) in this
cohort, and this end point also exhibited a strong dose-response trend. No other types of
lymphatic or hematopoietic cancer were clearly linked to benzene exposure. Quantitative risk
estimates were robust with respect to whether AMML or all leukemia was being modeled. They
were also robust with respect to whether the Paustenbach et al. or Crump and Allen exposure
estimates were used (differences in risk estimates of no greater than 2-fold) as long as linear
dose-response models were applied. However, whereas the Crump and Allen exposures
predicted a linear dose response, the Paustenbach et al. exposures predicted a quadratic dose
response. This departure from linearity was borderline significant (p=0.08). Estimates of
additional lifetime from 45 years of occupational exposure (lifetime exposure) to 1 ppm derived
using the Paustenbach et al. exposure matrix and best-fitting (quadratic) models ranged from
0.020 to 0.036 per thousand, whereas corresponding estimates based on a linear dose response
ranged from 1.6 to 3.1 per thousand. Environ Health Perspect 104(Suppl 6):1437-1441 (1996)
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Introduction
Crump and Allen (1) developed estimates
of the benzene-related risk of leukemia
using data from a cohort of workers
exposed to benzene during the manufac-
ture of Pliofilm, a glossy membrane made
from rubber hydrochloride and used
chiefly for packaging and other water-resis-
tant materials (2-5). This risk assessment
was used by the U.S. Occupational Safety
and Health Administration (6) to support
a reduction of the permissible exposure
limit (PEL) for benzene from 10 ppm to
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1 ppm; it also formed the basis for the
"unit risk estimate" for inhaled benzene
developed by the U.S. Environmental
Protection Agency (7).
Since the Crump and Allen risk assess-
ment (1), significant new information has
become available on the Pliofilm cohort.
First, follow-up of the cohort has been
extended by the National Institute
of Occupational Safety and Health
(NIOSH) from 1978 through 1987.
Second, Paustenbach et al. (8) made a
detailed reevaluation of exposures in the
Pliofilm cohort that incorporated informa-
tion obtained recently from historical
records and from interviews with former
workers. This assessment accounted for,
among other things, dermal exposures,
short-term, high-level exposures, respirator
use, biases ofsampling devices used in ear-
lier years, and a previously unaccounted for
shutdown of the St. Marys plant during
World War II. The present article summa-
rizes an update ofthe Crump andAllen risk
assessment (1) that incorporates 9 years of
additional follow-up and the new exposure
estimates developed by Paustenbach et al.
(8). Crump (9) presents a more detailed
description ofthis work.
Methods
The present analysis used mortality data
from follow-up by NIOSH of a cohort of
1717 white male workers employed in
Pliofilm operations for at least 1 day at
either the St. Marys or the Akron, Ohio
manufacturing facility (6). The total
included 577 workers in jobs not consid-
ered by Rinsky et al. (3,4) to involve ben-
zene exposure [although both Crump and
Allen (1) and Paustenbach et al. (8) esti-
mated some exposure to benzene in these
jobs] and for whom follow-up did not
extend beyond 31 December 1981. The
mortality experience ofthe 1140 remaining
workers was followed through 31 December
1987. Paxton et al. (5) provided a detailed
description of the status of the cohort
through the most recent follow-up.
The analysis focuses upon lymphatic
and hematopoietic cancer (International
Classification ofDiseases, 9th Revision, codes
202-209), all leukemias, and a category
of acute leukemia defined as acute mye-
logenous or acute monocytic leukemia
(AMML). AMML includes all ofthe acute
nonlymphocytic leukemias that have been
identified in the Pliofilm cohort. A lifetable
analysis is conducted for all three cancer cat-
egories and, based on the results of the
lifetable analysis, dose-response modeling is
conducted for all leukemias and forAMML.
The type ofleukemia is not known for 2 of
the 14 cases found in the most recent fol-
low-up, and these cases were excluded from
the dose-response modeling ofAMML.
Following the approach used by
Crump and Allen (1), both absolute risk
and cumulative risk models were used. An
additive risk model assumes that benzene
increases the background mortality rate by
an additive amount that depends on prior
benzene exposure; a multiplicative risk
model assumes that benzene increases the
background mortality rate by a multiplica-
tive factor that depends on prior benzene
exposure. Both linear and nonlinear ver-
sions ofeach ofthese models were consid-
ered. For the linear additive risk model, the
mortality rate at age t for the cancer of
interest is assumed to be in the form
h(t) = a(t) +PX(t),
where a(t) is the background mortality
rate at age t (which was estimated from
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appropriate mortality rates for white males
in the United States), X(t) is a summary
measure ofbenzene exposure before age t,
and P is a parameter that gauges the
carcinogenic potency of benzene. The
corresponding expression for the linear
multiplicative model is
h(t) = a(t) [1 +PX(t)].
The study also involved analyses that
incorporated a parameter that multiplied
a(t) to account for the possibility that the
background mortality rates in the Pliofilm
cohort differed systematically from total
U.S. rates (9). However, there was no evi-
dence that U.S. rates were not appropriate,
and those analyses are not discussed here.
The summary exposure measure, X(t),
discussed in the present report, is cumula-
tive exposure (ppm-years/m3) to age t, with
a 5-year lag (i.e., omitting exposures during
the 5 most recent years). Lags of 0 and 3
years were also considered, but they did not
describe the data as well as alag of5 years.
We also considered a form ofweighted
exposure that was based on the leukemia-
response pattern observed following X-ray
treatment (10). With weighted exposure,
the impact ofbenzene exposure occurring
during a small time slice on future cancer
mortality increases with increasing elapsed
time from zero impact to a maximum level
of impact and decreases thereafter. The
effect of the complete pattern of benzene
exposure is obtained by integrating the
effects ofexposures during each time slice.
In general, weighted exposure did not
describe the mortality data as well as cumu-
lative exposure and it produced risk esti-
mates roughly comparable to those obtained
using cumulative exposure. Estimates of
lifetime risk based on weighted exposure
could be either higher or lower than those
based on cumulative exposure, but gener-
ally the differences were less than a factor
of 2 (9). Only results based on cumulative
exposure are presented here.
To investigate the possibility of a non-
linear relationship between benzene expo-
sure and mortality rate, the linear models
described above were expanded to include
nonlinear terms. Two types ofnonlinearity
were considered. In nonlinearity that was
dependent on the area under exposure-
duration curve (AUC), additional terms
were incorporated that varied as the square
or cube of cumulative exposure. That is,
AUC-dependent, nonlinear models were
defined by replacing PX(t) in the linear
additive and multiplicative models by
X(t) + 532X2(t) + 13X3(t). Intensity-
dependent nonlinear models were described
the same way except that cumulative expo-
sure raised to apower, X'(t), was replaced by
Xi(t) = I5x'(v)dv
where x(v) is the intensity of exposure
(ppm) at age v (i.e., Xi(t) is the accumula-
tion [integral] of instantaneous exposure
raised to the ith power, where i = 2 or
i=3). With intensity-dependent nonlinear-
ity, the intensity of exposure was given
greater weight than the duration ofexpo-
sure. For example, at the completion ofthe
exposure period, X2(t) = 100 (ppm-years)2
both for exposure to 100 ppm for 1 year
and exposure to 10 ppm for 10 years.
However, X,2(t) = 10,000 ppm2-years for
the former exposure pattern and 1000
ppm -years for the latter pattern, which
represents a 10-fold difference. Intensity-
dependent nonlinearity may be more
appropriate than AUC-dependent nonlin-
earity for modeling biological effects
brought about by acute toxicity.
Analyses were performed using both the
Paustenbach et al. exposure matrix [the set
ofexposure estimates recently developed for
the Pliofilm cohort by Paustenbach et al.
(8)] and, for comparison purposes, the
Crump and Allen exposure matrix [the set
of exposures developed by Crump and
Allen (1)].
The method of maximum likelihood
was used to fit models to data and to test
hypotheses. Estimates ofthe potency para-
meters (,B and 3i) were translated into esti-
mates of the additional lifetime risk of
cancer from specific patterns of benzene
exposure (lifetime occupational exposure
and continuous lifetime exposure) using a
formula for the lifetime probability of
cancer based on United States mortality
rates (males and females combined) for
total mortality and for the cancer ofinterest.
In converting from occupational exposure
to continuous exposure, it was assumed that
Pliofilm workers were exposed for 8 hr/day,
250 days/year, and breathed 10 m3 of air
per 8-hr workday. It was further assumed
that persons exposed continuously breathe
20 m3 of air per 24-hr day. Additional
details regarding methods ofanalysis are
provided in Crump (9).
Results
Table 1 contains a list of the 21 cases of
lymphatic and hematopoietic cancer in the
cohort along with the cumulative benzene
exposures (zero lag) at time ofdeath com-
puted using both the Paustenbach et al.
and the Crump and Allen exposure matri-
ces. This table also indicates which ofthese
21 cases were AMML (8-10 cases) or leu-
kemia ofany type (14 cases). All the model
fits forAMML included only the eight con-
firmed cases and omitted the two question-
able cases. Both questionable cases involved
relatively low exposures to benzene.
Table 2 presents the results of the
lifetable analysis of the association ofvari-
ous categories of hematopoietic cancer,
with cumulative exposure defined using
the Paustenbach et al. exposure matrix. A
similar analysis (not shown) based on the
Crump and Allen exposure matrix gave
comparable results. A dose response was
observed for each of the three categories,
AMML, all leukemias, and total lymphatic
and hematopoietic cancer. However,
neither the dose response for all leukemias
nor that for total lymphatic and hemato-
poietic cancer was as strong as that for
AMML; and a dose response was not
apparent for either of these categories if
AMML was excluded. For the category
defined as total lymphatic and hematopoi-
etic cancer excluding leukemia, there was a
slight deficit of cancer deaths (observed
= 7, expected = 7.3), and there was no
indication ofa dose response (other than a
single case in the high-exposure group).
There was a nonsignificant excess for non-
AMML leukemias [expected = 3. 1,
observed = 4 (p= 0.38) to 6 (p=0.10)].
However, all ofthe non-AMML leukemias
were associated with exposures <400 ppm-
years, whereas five of the AMMLs were
associated with exposures > 1000 ppm-
years (only 0.06 expected). Thus, AMML
was the only response clearly related to
benzene exposure.
Table 3 contains results from fitting
linear versions ofthe additive risk and mul-
tiplicative risk models to responses of
AMML and all leukemias. Potency esti-
mates (estimates of 3) derived from the
Paustenbach et al. (8) exposure matrix are
smaller by a factor of <2 compared to the
corresponding estimates based on the
Crump and Allen exposure matrix (1).
Potency estimates derived from AMML
and all leukemias using the additive model
are in close agreement. Corresponding esti-
mates derived from multiplicative models
are not strictly comparable because the
increase in relative risk derived from all
leukemias multiplies a larger background
than the increase derived from only
AMML alone. Potency estimates derived
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Table 1. Summary of information on 21 cases of lymphatic and hematopoietic cancer in males.
Patient Rinsky etal. (4) Yearof Cumulative exposure, ppm-years
identification no. case no. Birth Death Firstemployment Lastemployment Crump and Allen (1) Paustenbach (8) Leukemia AMML-9
19 2 1921 1950 1948 1948 3 3 X
858 8 1~~~~~~~~925' 1195 1w162354X
689 7 1899 1957 1942 1948 307 570 X Y
136~~~~~1 1921 1S~~~~~~~~~~~ 1940- 194~~~~~~~~~~. 394~~...1.7.....
49 3 1898 1958 1945 1958 251 1054 X X
176 6 1904 1961 1941 1961 2155 1771 X X
280 11 1910 1963 1940 1940 0 0
826 ~~ ~ ~~~~12 190N190-j84 490 14 --Th
154 1908 1973 1937 1970 54 651
4591208 1 847196 175 3 ~ .>:;.~
184 9 1912 1979 1942 1960 325 1129 X X
48 10 1912 190B~~~~~~~~W.. 14 -1
949 13 1912 1981 1954 1955 16 12
024 1~~~~~~~~~91 1984 1901970---- 3
432 1918 1985 1940 1956 145 293 X
379 98 15 18815-* 58-XX
95 1914 1986 1945 1946 50 12 X
871 1905- ~~~~~ ~ ~~~~~198-7 199 94. x7
581 1926 1987 1947 1947 0 19
"Includes acute myelocytic (X) and acute monocytic (Y) leukemia.
Table 2. Observed and expected numbers of cancer deaths by cumulative exposure (Paustenbach exposure matrix) for different categories of lymphatic and
hematopoietic cancers.
Cumulative
exposure, Total lymphatic Total Leukemia
ppm-years Person- AMML Leukemia and hematopoietic excluding leukemia excluding AMML Total excluding AMML
range (mean) years Obs Exp RH Obs Exp RH Obs Exp RH Obs Exp HR Obs Exp RH Obs Exp RH
0-45(11) 30482 0-2 0.82 0.0-2.4 3 2.41 1.2 6 6.16 1.0 3 3.75 0.8 1-3 1.59 0.63-1.9 4-6 5.34 0.75-1.1
45--400.4151-): 16320. 1 051 2.0: 4: 1,.50 2.7 8 3::.83 1. T .2.-33 OS 3 OS3.05 321.
400-1000(602) 4867 2 0.22 9.1 2 0.65 3.1 3 1.65 1.8 1 0.99 1.0 0 0.43 0.0 1 1.43 0.7
>1000(11341)- 9115 5 0.06: 82.8 5 0.182-8.1 6 04 35 107a .2001 ( .
Total(132) 52584 8-10 1.61 5.0-6.2 14 4.75 2.9 21 12.09 1.7 7 7.34 1.0 4-6 3.14 1.3-1.9 11-13 10.48 1.05-1.2
Abbreviations: obs, number of observed cancer deaths; exp, number of expected cancer deaths based on U.S. sex- and age-specific rates; RH, obs/exp (relative risk). "AMML
and AML (ICD, codes 205.0 and 206.0); leukemia (ICD, codes 204-207); total lymphatic and hematopoietic cancers (ICD, codes 200-209).
from additive and multiplicative models
also are not comparable. It appears that in
each case the multiplicative model fits the
data considerably better than the additive
model (because higher likelihoods are
associated with multiplicative models,
although a formal statistical test is not pos-
sible because the models are not nested).
Consequently, results based on the multi-
plicative risk models will be emphasized in
the remainder ofthe paper.
Table 4 contains results from fitting
nonlinear versions ofthe multiplicative risk
model. There was no evidence of non-
linearity in models that employed AUC-
dependent nonlinearity. Similarly, no
evidence ofnonlinearity was evident from
application of models incorporating inten-
sity-dependent nonlinearity models to the
Crump and Allen exposure matrix.
However, the two analyses that combined
intensity-dependent nonlinearity with the
Paustenbach et al. exposure matrix detected
a marginally significant departure from a
purely linear model (p=O.08l and 0.085).
Using this combination, the best-fitting
models were quadratic for both AMML
and all leukemias. Although standard errors
are not provided in Table 4, the fact that
both of these p-values are slightly greater
than 0.05 implies that the 95% upper con-
fidence limits on the linear term in these
nonlinear models will be slightly greater
than the potency estimates derived from the
linear versions ofthese fits (Table 3).
Table 5 contains estimates of the
number of additional deaths per thousand
persons exposed occupationally to 1 ppm
benzene for 45 years (from age 20-65). For
comparison purposes, the estimate obtained
by Grump and Allen (1) from this cohort
based on a linear, cumulative exposure,
Table 3. Results from fits of linear models.
P (SE), Maximum
Exposure matrix ppm-years-1 likelihood
Crump and Allen 11)a
AMML
Additive model 2.OE-6 )8.2E-7) -64.00
Multiplicative model 4.5E-2 (1.8E-2) -61.84
All leukemias
Additive model 1 .9E-6 )8.8E-7) -115.18
Multiplicative model 1.7E-2 )6.8E-3) -111.68
Paustenbach et al. (8)a
AMML
Additive model 1 .3E-6 (5.1E-7) -64.46
Multiplicative model 2.7E-2 (1.OE-2) -61.68
All leukemias
Additive model 1.3E-6 (5SFE-7) -115.98
Multiplicative model 1.1E-2 )3.9E-3) -111.57
a1References indicate the method used for calculation
of data in table.
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Table 4. Results from fits of nonlinear multiplicative models.
AUC-dependent nonlinearity Intensity-dependent nonlinearity
Maximum Maximum
Exposure matrix p1 ,2 J3 likelihood p-valuea f1 12 13 likelihood p-valuea
Crump and Allen (1)b
AMML 4.OE-2 0.0 6.0E-9 -61.75 NSC 4.5E-2 0.0 0.0 -61.84 NS
All leukemias 1.7E-2 0.0 6.1E-10 -111.67 NS 1.7E-2 0.0 0.0 -111.68 NS
Paustenbach et al. (8)b
AMML 9.5E-3 2.4E-5 0.0 -61.34 NS 0.0 3.1E-4 0.0 -60.74 0.085
All leukemias 9.7E-3 1.OE-6 0.0 -111.57 NS 0.0 1.2E-4 0.0 -110.60 0.081
AMML, acute myelogenous/monocytic leukemia. 8p-Value for test for a significantly nonlinear dose response.
bReferences indicate the methods used for calculation of data in the table. CNS, p-value >0.1.
Table 5. Additional deaths expected per thousand
persons from occupational exposure to 1 ppm benzene
from age 20 through 65.
Linear Intensity-dependent
Exposure matrix model nonlinear model
Crump and Allen (1)a
AMML 4.3 4.3
All leukemias 5.1 5.1
All leukemias, 6.6
1978 follow-up
Paustenbach et al. (8)a
AMML 2.6 0.030
All leukemias 3.1 0.036
Estimates based on multiplicative model, cumulative
exposure with a 5-year lag. aReferences indicate the
methods used for calculation of data in the table.
multiplicative risk model is also presented.
The risk estimate obtained by Crump and
Allen (6.6/thousand) agrees closely with
the corresponding estimate obtained from
the current analysis using the Crump and
Allen exposure matrix (1) (5.1/thousand).
Estimates derived from data on AMML
and on all leukemias also agree closely.
Estimates from linear models based on the
Paustenbach et al. exposure matrix (8) are
roughly one-half ofthe corresponding esti-
mates based upon the Crump and Allen
exposure matrix (1). Risk estimates derived
from nonlinear models are far smaller with
the Paustenbach et al. exposure matrix (8)
than the Crump and Allen exposure matrix
(1). This is because the Paustenbach et al.
exposure matrix (8) produces a purely qua-
dratic dose response, whereas the Crump
and Allen exposure matrix (1) produces an
essentially linear dose response.
Table 6 contains estimates ofthe number
ofadditional deaths per 1 million persons
Table 6. Additional deaths expected per million
persons from continuous exposure to 1 ppb benzene.
Linear Intensity-dependent
Exposure matrix model nonlinear model
Crump and Allen (1)a
AMML 21.0 21.0
All leukemias 24.0 24.0
Paustenbach et al. (8)a
AMML 15.0 0.00014
All leukemias 15.0 0.00017
Estimates based on multiplicative model, cumulative
exposure with a 5-year lag. aReferences indicate the
methods used for calculation of data in the table.
exposed continuously throughout life to
1 ppb benzene. Estimates based on linear
models range from 15 per million using
the Paustenbach et al. (8) exposure matrix
to 21 to 24 per million based on the
Crump and Allen (1) exposure matrix.
Estimates based on nonlinear models and
the Paustenbach et al. (8) exposure matrix
are about 100,000 times smaller than
estimates based on linear models.
Discussion
The two exposure matrices lead to quite
different conclusions concerning the shape
ofthe dose response. Whereas dose responses
were essentially linear when the Crump and
Allen (1) exposure matrix was used, there
was evidence ofintensity-dependent nonlin-
earity in dose responses derived using the
Paustenbach et al. exposure matrix (Table
4); based on this matrix, each ofthe three
best-fitting models was quadratic, and
departures from linearity were borderline
significant in each case. Estimates of risk
from 45 years ofexposure at 1 ppm based
on these quadratic models were about
100-fold smaller than corresponding esti-
mates derived from linear models.
The Paustenbach et al. (8) exposure
matrix was based on a much more detailed
investigation than that conducted by
Crump and Allen (1). Based on review of
their work and personal knowledge of
methods used by Crump and Allen, we
believe that the Paustenbach et al. matrix is
likely to provide a better representation of
exposures in the cohort. Nevertheless, con-
siderable uncertainty exists with regard to
exposures during the earliest period ofplant
operation. Paxton et al. (5) showed that the
average exposure in the cohort based on the
Paustenbach et al. exposure matrix was
about 2-fold higher than that based on the
Crump and Allen exposure matrix and
about 4-fold higher than that based on the
Rinsky et al. (4) exposure matrix.
The Rinsky et al. (4) exposure matrix,
which was not used in this analysis, did not
conform with blood count data for this
cohort or with the Crump and Allen (1)
exposure matrix. Based on a study of over
17,000 peripheral blood counts collected
from 459 workers at St. Marys between
1940 and 1975, Kipen et al. (11) showed
that assignment of relatively higher ben-
zene exposures to this cohort during the
1940s, with a substantial and rapid decline
in these exposures after 1946 [as assumed
by Crump and Allen (1)], was consistent
with temporal increases in blood counts.
Using a different method of analysis,
Hornung (unpublished data) showed that
the exposures predicted by the Rinsky et al.
exposure matrix also were correlated with
blood counts. However, Hornung did not
use his method to evaluate the other two
exposure matrices.
The large differences in risk obtained in
this study between linear and nonlinear
models are extremely important to the reg-
ulation ofbenzene. Unfortunately, it is not
possible to accurately determine the amount
ofnonlinearity present in the dose response
based on the information available from
the Pliofilm cohort. Perhaps continued fol-
low-up ofthe much larger Chinese cohort
(R Hayes, unpublished data) will help fur-
ther narrow the range of risks associated
with human exposure to benzene.
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